WASHINGTON (AP) — Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular dystrophy, sending company shares plummeting in morning trading.
A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Thursday after Royal Bank of Canada lowered their price target on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback